Jacobs Levy Equity Management, Inc Unity Biotechnology, Inc. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.3 - $3.17 $703,976 - $1.72 Million	-541,520 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.91 - $4.5 $635,538 - $982,791	-218,398 Reduced 28.74%	541,520 $1.63 Million
Q2 2021 Aug 16, 2021	BUY	$4.15 - $6.3 $765,571 - $1.16 Million	184,475 Added 32.06%	759,918 $3.53 Million
Q1 2021 May 17, 2021	BUY	$5.51 - $9.42 $994,477 - $1.7 Million	180,486 Added 45.7%	575,443 $3.45 Million
Q4 2020 Feb 16, 2021	BUY	$3.42 - $6.36 $957,870 - $1.78 Million	280,079 Added 243.81%	394,957 $2.07 Million
Q3 2020 Nov 16, 2020	SELL	$2.94 - $12.43 $397,996 - $1.68 Million	-135,373 Reduced 54.09%	114,878 $397,000
Q2 2020 Aug 17, 2020	SELL	$5.28 - $9.67 $342,122 - $626,577	-64,796 Reduced 20.57%	250,251 $2.17 Million
Q1 2020 May 15, 2020	SELL	$5.0 - $7.6 $112,245 - $170,612	-22,449 Reduced 6.65%	315,047 $1.83 Million
Q4 2019 Feb 14, 2020	BUY	$5.99 - $8.38 $2.02 Million - $2.83 Million	337,496 New	337,496 $2.43 Million
Q2 2019 Aug 13, 2019	SELL	$7.59 - $10.21 $261,855 - $352,245	-34,500 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$7.65 - $16.66 $263,925 - $574,770	34,500 New	34,500 $280,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $17M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.